Eli Lilly's dominance in the GLP-1 market and strong revenue growth forecast make LLY stock a promising investment, with a ...

Medicare now covers Eli Lilly's Zepbound for obstructive sleep apnea, FDA-approved for obesity and sleep apnea treatment, ...

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions ...

Comparing Tyrzepatide and Semaglutide in the slimming drug market, with potential growth driven by increasing obesity rates worldwide. Explore more here.

Citi downgraded Hims & Hers to Sell from Neutral with a price target of $25, up from $24. The firm thinks the market is overvaluing the ...

The FDA rejected sotagliflozin (Zynquista) as an adjunct to insulin therapy for glycemic control in adults with type 1 ...

( MENAFN - Zex PR Wire) This revolutionary program is designed to deliver effective, science-based weight loss solutions at an accessible price.

Obesity is more than a cosmetic concern. It’s a chronic disease that can be treated with drugs like semaglutide (Wegovy) and ...

Given that more than 40% of Indian adults are struggling with obesity and diabetes, affordable weight-loss drugs are expected ...

Stay updated on the latest developments in the GLP-1 drug class, including a new generic entering the market, weight loss results, FDA decisions & cost issues.

at a significantly lower cost — around $250 to $350 per month for tirzepatide, compared to Zepbound's list price of $1,059. With the official shortage over, the FDA has signaled it will crack ...

The Dow Jones Industrial Average lost 696.75 points, or 1.63%, to close at 41,938.45. The S&P 500 slid 1.54% to 5,827.04, ...